Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
Novo Nordisk saw its sales climb 10.4% to 97.8 billion yen in Japan in 2020, becoming one of a small number of pharma companies to rack up growth in the falling market, with multiple diabetes drugs launched since 2019 giving…
To read the full story
Related Article
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
April 25, 2024
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
BUSINESS
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
- Chugai’s Hemlibra Successor Shows Promise in PI/II Study
February 10, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…